Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2174/1389450122666210215112150 http://scihub22266oqcxt.onion/10.2174/1389450122666210215112150 33588727!ä!33588727 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Drug+Targets 2021 ; 22 (17): 1986-2005 Nephropedia Template TP {{tp|p=33588727|t=2021. Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19 |pdf=|usr=}}{{33588727}} gab.com Text Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19 JO: Curr Drug Targets http://www.kidney.de/pget.php?&tw=1&pmid=33588727 #FOAvip The coronavirus disease 2019 (COVID-19) pandemic, due to the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in December 2019 and has rapidly spread globally. As the confirmed number of cases has reached 83 million worldwide, the potential severity and the deadly complications of the disease requires urgent development of effective drugs for prevention and treatment. No proven effective treatment for this virus currently exists. Most of the antiviral discovery efforts are focused on the repurposing of approved or clinical stage drugs. This review highlights the small-molecule repurposed antiviral agents that are currently under investigation in clinical trials for COVID-19. These include viral polymerase and protease inhibitors remdesivir, galidesivir, favipiravir, ribavirin, sofosbuvir, tenofovir/emtricitabine, baloxavir marboxil, EIDD-2801, lopinavir/ritonavir; virus-/host-directed viral entry and fusion inhibitors arbidol chloroquine/hydroxychloroquine, chlorpromazine, camostat mesylate, nafamostat mesylate, bromhexine and agents with diverse/unclear mechanism of actions as oseltamivir, triazavirin, ivermectin, nitazoxanide, niclosamide and BLD-2660. The published preclinical and clinical data to date on these drugs as well as the mechanisms of action are reviewed. Twit Text FOAVip Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19 ????Curr Drug Targets http://www.kidney.de/pget.php?&tw=1&pmid=33588727 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33588727 #FOAvip English Wikipedia <ref>{{Cite pmid|33588727}}</ref> Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19 #MMPMID33588727 Apaydin CB; Cinar G; Cihan-Ustundag G Curr Drug Targets 2021[]; 22 (17): 1986-2005 PMID33588727show ga The coronavirus disease 2019 (COVID-19) pandemic, due to the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in December 2019 and has rapidly spread globally. As the confirmed number of cases has reached 83 million worldwide, the potential severity and the deadly complications of the disease requires urgent development of effective drugs for prevention and treatment. No proven effective treatment for this virus currently exists. Most of the antiviral discovery efforts are focused on the repurposing of approved or clinical stage drugs. This review highlights the small-molecule repurposed antiviral agents that are currently under investigation in clinical trials for COVID-19. These include viral polymerase and protease inhibitors remdesivir, galidesivir, favipiravir, ribavirin, sofosbuvir, tenofovir/emtricitabine, baloxavir marboxil, EIDD-2801, lopinavir/ritonavir; virus-/host-directed viral entry and fusion inhibitors arbidol chloroquine/hydroxychloroquine, chlorpromazine, camostat mesylate, nafamostat mesylate, bromhexine and agents with diverse/unclear mechanism of actions as oseltamivir, triazavirin, ivermectin, nitazoxanide, niclosamide and BLD-2660. The published preclinical and clinical data to date on these drugs as well as the mechanisms of action are reviewed. |*Antiviral Agents/pharmacology/therapeutic use[MESH] |*COVID-19 Drug Treatment[MESH] |Clinical Trials as Topic[MESH] |Drug Repositioning[MESH] |Humans[MESH] |Pandemics[MESH]Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-1(epmc).pdf DeepDyve Pubget Overpricing